| 1 |
Kapcan E, Rullo AF. A covalent opsonization approach to enhance synthetic immunity against viral escape variants. Cell Rep Phys Sci 2023;4:101258. [PMID: 36741337 DOI: 10.1016/j.xcrp.2023.101258] [Reference Citation Analysis]
|
| 2 |
Santos JLF, Zanardi P, Alo V, Dos Santos V, Bovone L, Rodriguez M, Magdaleno F, De Langhe V, Villoldo A, Martinez Souvielle R, Alconcher J, Quiros D, Milicchio C, Garcia Saiz E. Lung Injury in COVID-19 Has Pulmonary Edema as an Important Component and Treatment with Furosemide and Negative Fluid Balance (NEGBAL) Decreases Mortality. J Clin Med 2023;12. [PMID: 36836076 DOI: 10.3390/jcm12041542] [Reference Citation Analysis]
|
| 3 |
Abu-Serie MM, Habashy NH. Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury. Int J Biol Macromol 2023;228:715-31. [PMID: 36584778 DOI: 10.1016/j.ijbiomac.2022.12.251] [Reference Citation Analysis]
|
| 4 |
Machado TL, Santos AC, Azamor T, da Silva AMV, Pimenta VR, Tubarão LN, da Silva ADS, Flores Rodrigues DDR, Müller R, Pinto MA, Villar LM, Bom APA, Melgaço JG. CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy. J Med Virol 2023;95:e28427. [PMID: 36571274 DOI: 10.1002/jmv.28427] [Reference Citation Analysis]
|
| 5 |
Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infection 2023;51:21-35. [PMID: 35438413 DOI: 10.1007/s15010-022-01825-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Manca F, Pawlak J, Sivakumar A. Impact of perceptions and attitudes on air travel choices in the post-COVID-19 era: A cross-national analysis of stated preference data. Travel Behav Soc 2023;30:220-39. [PMID: 36247181 DOI: 10.1016/j.tbs.2022.10.006] [Reference Citation Analysis]
|
| 7 |
Bahakel H, Murphy C, Frenck RW Jr, Grimley MS, Marsh RA, Paulsen GC, Haslam DB, Phillips CL, Courter J, Spearman P, Schulert G, Danziger-Isakov L. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. Pediatr Infect Dis J 2022;41:985-8. [PMID: 36219876 DOI: 10.1097/INF.0000000000003703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Al-Taie A, Büyük AŞ, Sardas S. Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Pulm Pharmacol Ther 2022;77:102172. [PMID: 36265833 DOI: 10.1016/j.pupt.2022.102172] [Reference Citation Analysis]
|
| 9 |
Campagna R, Mazzuti L, Guerrizio G, Nonne C, Migliara G, De Vito C, Mezzaroma I, Chiaretti S, Fimiani C, Pistolesi V, Morabito S, Turriziani O. Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations. Vaccine X 2022;12:100246. [PMID: 36506461 DOI: 10.1016/j.jvacx.2022.100246] [Reference Citation Analysis]
|
| 10 |
Li PC, Wang HS, Shibu MA, Wang J, Huang SH, Wang JH, Wang JH, Huang CY, Chiang CY, Lin YJ, Ho TJ, Lin SZ, Chung HC, Yu HY, Su SH, Chou YF, Tai CH, Ding DC, Shih CY. Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study. J Herb Med 2022;36:100610. [PMID: 36341465 DOI: 10.1016/j.hermed.2022.100610] [Reference Citation Analysis]
|
| 11 |
Scotto R, Buonomo AR, Zumbo G, Di Fusco A, Esposito N, Di Filippo I, Nobile M, Pinchera B, Schiano Moriello N, Villari R, Gentile I, Federico Ii Covid Team. Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge. Vaccines (Basel) 2022;10. [PMID: 36366403 DOI: 10.3390/vaccines10111895] [Reference Citation Analysis]
|
| 12 |
Kara S, Lazovic G, Chohan F, Lawrence JA, Sukaina M, Edaki O, Nedd K. Third wave COVID-19 delta variant breakthrough infection in a Hispanic-dominant suburb of Miami, Florida: ethical dilemma and vaccination hesitancy. Ther Adv Vaccines Immunother 2022;10:25151355221128086. [PMID: 36225944 DOI: 10.1177/25151355221128086] [Reference Citation Analysis]
|
| 13 |
Zare Marzouni H, Rahbar M, Seddighi N, Nabizadeh M, Meidaninikjeh S, Sabouni N. Antibody Therapy for COVID-19: Categories, Pros, and Cons. Viral Immunol 2022. [PMID: 36201297 DOI: 10.1089/vim.2021.0160] [Reference Citation Analysis]
|
| 14 |
Chavda VP, Patel AB, Pandya A, Vora LK, Patravale V, Tambuwala ZM, Aljabali AA, Serrano-Aroca Á, Mishra V, Tambuwala MM. Co-infection associated with SARS-CoV-2 and their management. Future Sci OA 2022;8:FSO819. [PMID: 36788985 DOI: 10.2144/fsoa-2022-0011] [Reference Citation Analysis]
|
| 15 |
Lamour D, Vafadari N, Clayton LM, Solano JJ, Hughes PG, Shih RD, Alter SM. The Treatment of COVID-19 With Monoclonal Antibody Therapy: Patient-Reported Outcomes. Cureus 2022. [DOI: 10.7759/cureus.29247] [Reference Citation Analysis]
|
| 16 |
González-gonzález E, Carballo-uicab G, Salinas-trujano J, Cortés-paniagua MI, Vázquez-leyva S, Vallejo-castillo L, Mendoza-salazar I, Gómez-castellano K, Pérez-tapia SM, Almagro JC. In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library. Antibodies 2022;11:57. [DOI: 10.3390/antib11030057] [Reference Citation Analysis]
|
| 17 |
Mokhtary P, Pourhashem Z, Mehrizi AA, Sala C, Rappuoli R. Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. Biomedicines 2022;10. [PMID: 36009408 DOI: 10.3390/biomedicines10081861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Reddy R, Mintz J, Golan R, Firdaus F, Ponce R, Van Booven D, Manoharan A, Issa I, Blomberg BB, Arora H. Antibody Diversity in Cancer: Translational Implications and Beyond. Vaccines 2022;10:1165. [DOI: 10.3390/vaccines10081165] [Reference Citation Analysis]
|
| 19 |
Wang T, Chen J, Du X, Feng G, Dai T, Li X, Liu D. How neutron scattering techniques benefit investigating structures and dynamics of monoclonal antibody. Biochim Biophys Acta Gen Subj 2022;1866:130206. [PMID: 35872327 DOI: 10.1016/j.bbagen.2022.130206] [Reference Citation Analysis]
|
| 20 |
Kirillova A, Lado A, Blatt N. Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. Bionanoscience 2022;:1-19. [PMID: 35729973 DOI: 10.1007/s12668-022-00997-9] [Reference Citation Analysis]
|
| 21 |
Yang J, Lin S, Sun H, Chen Z, Yang F, Lin X, Guo L, Wang L, Wen A, Zhang X, Dai Y, He B, Cao Y, Dong H, Liu X, Chen B, Li J, Zhao Q, Lu G. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. Front Immunol 2022;13:820336. [PMID: 35663966 DOI: 10.3389/fimmu.2022.820336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 22 |
Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Rajvi P. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther 2022. [PMID: 35604379 DOI: 10.1080/14712598.2022.2078160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 23 |
McCarthy MW. Outpatient treatment options to address the SARS-CoV-2 variant Omicron. Expert Rev Anti Infect Ther 2022. [PMID: 35549623 DOI: 10.1080/14787210.2022.2077191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Pidiyar V, Kumraj G, Ahmed K, Ahmed S, Shah S, Piyali, Majumder, Verma B, Pathak S, Mukherjee S. COVID-19 management landscape- A need for an affordable to manufacture safe and efficacious bio-therapeutic and prophylactic for developing countries. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.05.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Filchtinski D, Sundberg M, Berthold H, Steller L, Kayser J, Holz S, Hinze M, Braeutigam O, Schulte-Pelkum J, Fiedler R. Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples. J Immunol Methods 2022;504:113258. [PMID: 35304119 DOI: 10.1016/j.jim.2022.113258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 26 |
Abdelrahim M, Esmail A, Al Saadi N, Zsigmond E, Al Najjar E, Bugazia D, Al-Rawi H, Alsaadi A, Kaseb AO. Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. Front Pharmacol 2022;13:848676. [PMID: 35462919 DOI: 10.3389/fphar.2022.848676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Sberna G, Biagi M, Marafini G, Nardacci R, Biava M, Colavita F, Piselli P, Miraldi E, D'Offizi G, Capobianchi MR, Amendola A. In vitro Evaluation of Antiviral Efficacy of a Standardized Hydroalcoholic Extract of Poplar Type Propolis Against SARS-CoV-2. Front Microbiol 2022;13:799546. [PMID: 35350622 DOI: 10.3389/fmicb.2022.799546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Sarker A, Rathore AS, Khalid MF, Gupta RD. Structure-guided affinity maturation of a single-chain variable fragment antibody against the Fu-bc epitope of the dengue virus envelope protein. J Biol Chem 2022;:101772. [PMID: 35218775 DOI: 10.1016/j.jbc.2022.101772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. [DOI: 10.2217/imt-2021-0168] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 30 |
Mendoza-salazar I, Gómez-castellano KM, González-gonzález E, Gamboa-suasnavart R, Rodríguez-luna SD, Santiago-casas G, Cortés-paniagua MI, Pérez-tapia SM, Almagro JC. Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library. Antibodies 2022;11:13. [DOI: 10.3390/antib11010013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Arostegui D, Castro K, Schwarz S, Vaidy K, Rabinowitz S, Wallach T. Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection. JPGN Reports 2022;3:e152. [DOI: 10.1097/pg9.0000000000000152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 32 |
Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100086] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 33 |
Martin-Vicente M, Almansa R, Martínez I, Tedim AP, Bustamante E, Tamayo L, Aldecoa C, Gómez JM, Renedo G, Berezo JÁ, Cedeño JA, Mamolar N, García Olivares P, Herrán-Monge R, Cicuendez R, Enríquez P, Ortega A, Jorge N, Doncel C, de la Fuente A, Bustamante-Munguira J, Muñoz-Gómez MJ, González-Rivera M, Puertas C, Más V, Vázquez M, Pérez-García F, Rico-Feijoo J, Martín S, Motos A, Fernandez-Barat L, Eiros JM, Dominguez-Gil M, Ferrer R, Barbé F, Trapiello W, Kelvin DJ, Bermejo-Martin JF, Resino S, Torres A. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med 2022;291:232-40. [PMID: 34611927 DOI: 10.1111/joim.13386] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 34 |
Wisnewski AV, Liu J, Lucas C, Klein J, Iwasaki A, Cantley L, Fazen L, Campillo Luna J, Slade M, Redlich CA. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses. PLoS One 2022;17:e0262657. [PMID: 35041700 DOI: 10.1371/journal.pone.0262657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 35 |
Tamir H, Melamed S, Erez N, Politi B, Yahalom-ronen Y, Achdout H, Lazar S, Gutman H, Avraham R, Weiss S, Paran N, Israely T. Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection. Viruses 2022;14:189. [DOI: 10.3390/v14020189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 36 |
Shaharir SS, Johdi NA, Mohd R. Monoclonal Antibody. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00146-4] [Reference Citation Analysis]
|
| 37 |
Morin S, Lallemant M, Garcia-Prats A, Lewis L, Watkins M, Giaquinto C, Valentin M, Penazzato M, Reeder JC; Global Accelerator for Paediatric Formulations (GAP-f). Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children. Pediatr Infect Dis J 2022;41:e1-5. [PMID: 34784302 DOI: 10.1097/INF.0000000000003331] [Reference Citation Analysis]
|
| 38 |
Gupta J. Safety and sagacious use of remdesivir: Paramount focus on contemporary perspectives. Biomed Biotechnol Res J 2022;6:1. [DOI: 10.4103/bbrj.bbrj_161_21] [Reference Citation Analysis]
|
| 39 |
Serra A, Fratello M, Federico A, Ojha R, Provenzani R, Tasnadi E, Cattelani L, Del Giudice G, Kinaret PAS, Saarimäki LA, Pavel A, Kuivanen S, Cerullo V, Vapalahti O, Horvath P, Lieto AD, Yli-Kauhaluoma J, Balistreri G, Greco D. Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. Brief Bioinform 2021:bbab507. [PMID: 34962256 DOI: 10.1093/bib/bbab507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 40 |
Garza JT, Quick J, Chatterjee D, Garr RP, Varadhachary A, Linbeck L. Assessing Immunity by Quantitative Measurement of SARS-CoV-2 IgG Antibodies in Fingerstick Samples.. [DOI: 10.1101/2021.12.21.21268075] [Reference Citation Analysis]
|
| 41 |
Sinclair NRS. Beginnings of coinhibition. Scand J Immunol 2021;94:e13098. [PMID: 34940993 DOI: 10.1111/sji.13098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 42 |
Xu T, Han L, George Thompson AM, Sun L. An improved capillary isoelectric focusing-mass spectrometry method for high-resolution characterization of monoclonal antibody charge variants. Anal Methods 2021. [PMID: 34939625 DOI: 10.1039/d1ay01556g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Pourgholaminejad A, Pahlavanneshan S, Basiri M. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges. Scand J Immunol 2021;:e13131. [PMID: 34936112 DOI: 10.1111/sji.13131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 44 |
Rando HM, Wellhausen N, Ghosh S, Lee AJ, Dattoli AA, Hu F, Byrd JB, Rafizadeh DN, Lordan R, Qi Y, Sun Y, Brueffer C, Field JM, Ben Guebila M, Jadavji NM, Skelly AN, Ramsundar B, Wang J, Goel RR, Park Y, Boca SM, Gitter A, Greene CS; COVID-19 Review Consortium Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen. Identification and Development of Therapeutics for COVID-19. mSystems 2021;6:e0023321. [PMID: 34726496 DOI: 10.1128/mSystems.00233-21] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 45 |
Mukherjee A, Verma A, Bihani S, Burli A, Mantri K, Srivastava S. Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches. Drug Discov Today Technol 2021;39:1-12. [PMID: 34906319 DOI: 10.1016/j.ddtec.2021.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 46 |
Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer PJ, Lheriteau E, Raffi F, Bruzzone R, Mok CKP, Duvaux O, Marcelin AG, Calvez V. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. Front Immunol 2021;12:761250. [PMID: 34868003 DOI: 10.3389/fimmu.2021.761250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 47 |
Liu H, Zhu W, Wu Y, Jiang C, Huo L, Belal A. COVID-19 Pandemic Between Severity Facts and Prophylaxis. Natural Product Communications 2021;16:1934578X2110412. [DOI: 10.1177/1934578x211041270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 48 |
Wu HH, Ralph KL, Sepuldeva E, Hansen G, Li H, Huang ZF, Liu D, Dziegelewski M, Ahlberg J, Frego L, Fogal S, van Tongeren S, Grimaldi C, Litzenberger T, Presky D, Singh S, Brodeur S, Kroe-Barrett R. An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. Int J Pharm 2021;609:121162. [PMID: 34624444 DOI: 10.1016/j.ijpharm.2021.121162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
More RV, Barrio-Zhang A, Ahmadzadegan A, Dabiri S, Ardekani AM. Monitoring heterogeneity in therapeutic samples using Schlieren. Int J Pharm 2021;609:121096. [PMID: 34562558 DOI: 10.1016/j.ijpharm.2021.121096] [Reference Citation Analysis]
|
| 50 |
Deb P, Molla MMA, Saif-ur-rahman K, Das MC, Das D. A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. Egypt J Bronchol 2021;15. [DOI: 10.1186/s43168-021-00090-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Martí D, Alsina M, Alemán C, Bertran O, Turon P, Torras J. Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies. Biochimie 2021:S0300-9084(21)00249-2. [PMID: 34710552 DOI: 10.1016/j.biochi.2021.10.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 52 |
Sutarlie L, Siak-Wie Ow D, Kong Ng S, Yang Y, Su X. Gold Nanoparticle-based "Mix and Measure" Fluorimetric Assays to Quantify Antibody Titer. Chem Asian J 2021;16:3188-93. [PMID: 34423583 DOI: 10.1002/asia.202100717] [Reference Citation Analysis]
|
| 53 |
Reka G, Pawlak A, Machowiec P, Maksymowicz M, Piecewicz-szczesna H. Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature. Current Issues in Pharmacy and Medical Sciences 2021;34:138-41. [DOI: 10.2478/cipms-2021-0030] [Reference Citation Analysis]
|
| 54 |
Carta A, Conversano C. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res 2021;21:986. [PMID: 34537034 DOI: 10.1186/s12913-021-06998-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 55 |
Esposito S, Abu-Raya B, Bonanni P, Cahn-Sellem F, Flanagan KL, Martinon Torres F, Mejias A, Nadel S, Safadi MAP, Simon A. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front Immunol 2021;12:708939. [PMID: 34456918 DOI: 10.3389/fimmu.2021.708939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Marcianò G, Roberti R, Palleria C, Mirra D, Rania V, Casarella A, De Sarro G, Gallelli L. SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. Applied Sciences 2021;11:7457. [DOI: 10.3390/app11167457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 57 |
Wisnewski AV, Liu J, Lucas C, Klein J, Iwasaki A, Cantley L, Fazen L, Luna JC, Slade M, Redlich CA. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses.. [DOI: 10.1101/2021.08.05.21261616] [Reference Citation Analysis]
|
| 58 |
Esposito S, Zona S, Pession A, Iughetti L, Migliori GB, Principi N. Use of Monoclonal Antibody to Treat COVID-19 in Children and Adolescents: Risk of Abuse of Prescription and Exacerbation of Health Inequalities. Pharmaceuticals (Basel) 2021;14:673. [PMID: 34358099 DOI: 10.3390/ph14070673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 59 |
Vanden Eynde JJ. COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes? Pharmaceuticals (Basel) 2021;14:664. [PMID: 34358090 DOI: 10.3390/ph14070664] [Reference Citation Analysis]
|
| 60 |
Forchette L, Sebastian W, Liu T. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Curr Med Sci 2021. [PMID: 34241776 DOI: 10.1007/s11596-021-2395-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 61 |
Morena F, Argentati C, Tortorella I, Emiliani C, Martino S. De novo ssRNA Aptamers against the SARS-CoV-2 Main Protease: In Silico Design and Molecular Dynamics Simulation. Int J Mol Sci 2021;22:6874. [PMID: 34206794 DOI: 10.3390/ijms22136874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Keeler SP, Fox JM. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Viruses 2021;13:1037. [PMID: 34072720 DOI: 10.3390/v13061037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 63 |
Costa B, Vale N. A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19. Pharmaceutics 2021;13:815. [PMID: 34070725 DOI: 10.3390/pharmaceutics13060815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 64 |
Phan AT, Gukasyan J, Arabian S, Wang S, Neeki MM. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia. Cureus 2021;13:e15280. [PMID: 34194882 DOI: 10.7759/cureus.15280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 65 |
Vittoria BL, Imbesi C, Irene G, Calì G, Bitto A. New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2021;14:503. [PMID: 34070359 DOI: 10.3390/ph14060503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 66 |
Bian H, Zheng ZH, Wei D, Wen A, Zhang Z, Lian JQ, Kang WZ, Hao CQ, Wang J, Xie RH, Dong K, Xia JL, Miao JL, Kang W, Li G, Zhang D, Zhang M, Sun XX, Ding L, Zhang K, Jia J, Ding J, Li Z, Jia Y, Liu LN, Zhang Z, Gao ZW, Du H, Yao N, Wang Q, Wang K, Geng JJ, Wang B, Guo T, Chen R, Zhu YM, Wang LJ, He Q, Yao RR, Shi Y, Yang XM, Zhou JS, Ma YN, Wang YT, Liang X, Huo F, Wang Z, Zhang Y, Yang X, Zhang Y, Gao LH, Wang L, Chen XC, Tang H, Liu SS, Wang QY, Chen ZN, Zhu P. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal Transduct Target Ther 2021;6:194. [PMID: 34001849 DOI: 10.1038/s41392-021-00603-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 67 |
Hagens A, İnkaya AÇ, Yildirak K, Sancar M, van der Schans J, Acar Sancar A, Ünal S, Postma M, Yeğenoğlu S. COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey. Vaccines (Basel) 2021;9:399. [PMID: 33919586 DOI: 10.3390/vaccines9040399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 68 |
Peter AS, Roth E, Schulz SR, Fraedrich K, Steinmetz T, Damm D, Hauke M, Richel E, Mueller-schmucker S, Habenicht K, Eberlein V, Issmail L, Uhlig N, Dolles S, Grüner E, Peterhoff D, Ciesek S, Hoffmann M, Pöhlmann S, Mckay PF, Shattock RJ, Wölfel R, Wagner R, Eichler J, Schuh W, Neipel F, Ensser A, Mielenz D, Tenbusch M, Winkler TH, Grunwald T, Überla K, Jäck H. A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.. [DOI: 10.1101/2021.04.16.440101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 69 |
Serra A, Fratello M, Federico A, Ojha R, Provenzani R, Tasnadi E, Cattelani L, del Giudice G, Kinaret PAS, Saarimäki LA, Pavel A, Cerullo V, Vapalahti O, Horvarth P, Di Lieto A, Yli-kauhaluoma J, Balistreri G, Greco D. Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.. [DOI: 10.1101/2021.04.15.440004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 70 |
Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer P, Lheriteau E, Raffi F, Bruzzone R, Pun Mok CK, Duvaux O, Marcelin A, Calvez V. XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants.. [DOI: 10.1101/2021.04.02.437747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 71 |
Nyabi O, Bentahir M, Ambroise J, Bearzatto B, Chibani N, Smits B, Durant JF, Vybornov A, Thellin O, El Moualij B, Gala JL. Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region. Int J Environ Res Public Health 2021;18:3372. [PMID: 33805139 DOI: 10.3390/ijerph18073372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 72 |
Martin-vicente M, Almansa R, Martínez I, Tedim AP, Bustamante E, Tamayo L, Aldecoa C, Gómez JM, Renedo G, Berezo JÁ, Cedeño JA, Mamolar N, Olivares PG, Herrán R, Cicuendez R, Enríquez P, Ortega A, Jorge N, de la Fuente A, Bustamante-munguira J, Muñoz-gómez MJ, González-rivera M, Puertas C, Más V, Vázquez M, Pérez-garcía F, Rico-feijoo J, Martín S, Motos A, Fernandez-barat L, Eiros JM, Dominguez-gil M, Ferrer R, Barbé F, Kelvin DJ, Bermejo-martin JF, Resino S, Torres A. Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients.. [DOI: 10.1101/2021.03.08.21253121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 73 |
Rando HM, Wellhausen N, Ghosh S, Lee AJ, Dattoli AA, Hu F, Byrd JB, Rafizadeh DN, Qi Y, Sun Y, Field JM, Guebila MB, Jadavji NM, Lordan R, Skelly AN, Ramsundar B, Brueffer C, Wang J, Goel RR, Park Y, Boca SM, Gitter A, Greene CS; COVID-19 Review Consortium. Identification and Development of Therapeutics for COVID-19. ArXiv 2021. [PMID: 33688554] [Reference Citation Analysis]
|
